Treace Medical Concepts, Inc.

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, TMCI is priced at $1.93, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, TMCI's ROE is -0.62%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BSX-PA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ABT has a market cap of 150.2B. Regarding current trading prices, TMCI is priced at $1.93, while ABT trades at $86.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ABT's P/E ratio is 24.16. In terms of profitability, TMCI's ROE is -0.62%, compared to ABT's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ABT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SYK has a market cap of 111.9B. Regarding current trading prices, TMCI is priced at $1.93, while SYK trades at $292.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SYK's P/E ratio is 34.80. In terms of profitability, TMCI's ROE is -0.62%, compared to SYK's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SYK's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, MDT has a market cap of 99.6B. Regarding current trading prices, TMCI is priced at $1.93, while MDT trades at $77.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas MDT's P/E ratio is 21.68. In terms of profitability, TMCI's ROE is -0.62%, compared to MDT's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check MDT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BSX has a market cap of 83.3B. Regarding current trading prices, TMCI is priced at $1.93, while BSX trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BSX's P/E ratio is 23.44. In terms of profitability, TMCI's ROE is -0.62%, compared to BSX's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BSX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BRKRP has a market cap of 50.1B. Regarding current trading prices, TMCI is priced at $1.93, while BRKRP trades at $330.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BRKRP's P/E ratio is N/A. In terms of profitability, TMCI's ROE is -0.62%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, TMCI is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BRKRP's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, EW has a market cap of 48B. Regarding current trading prices, TMCI is priced at $1.93, while EW trades at $83.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas EW's P/E ratio is 44.97. In terms of profitability, TMCI's ROE is -0.62%, compared to EW's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check EW's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PHG has a market cap of 25.9B. Regarding current trading prices, TMCI is priced at $1.93, while PHG trades at $27.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PHG's P/E ratio is 24.97. In terms of profitability, TMCI's ROE is -0.62%, compared to PHG's ROE of +0.08%. Regarding short-term risk, TMCI is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PHG's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, DXCM has a market cap of 23.3B. Regarding current trading prices, TMCI is priced at $1.93, while DXCM trades at $60.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas DXCM's P/E ratio is 25.89. In terms of profitability, TMCI's ROE is -0.62%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, TMCI is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check DXCM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, STE has a market cap of 21.1B. Regarding current trading prices, TMCI is priced at $1.93, while STE trades at $214.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas STE's P/E ratio is 30.25. In terms of profitability, TMCI's ROE is -0.62%, compared to STE's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check STE's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, TMCI is priced at $1.93, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ABMD's P/E ratio is 65.36. In terms of profitability, TMCI's ROE is -0.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ABMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ZBH has a market cap of 16B. Regarding current trading prices, TMCI is priced at $1.93, while ZBH trades at $82.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ZBH's P/E ratio is 21.51. In terms of profitability, TMCI's ROE is -0.62%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, TMCI is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ZBH's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, TMCI is priced at $1.93, while SNN trades at $30.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SNN's P/E ratio is 21.15. In terms of profitability, TMCI's ROE is -0.62%, compared to SNN's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SNN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, TMCI is priced at $1.93, while PEN trades at $324.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PEN's P/E ratio is 71.58. In terms of profitability, TMCI's ROE is -0.62%, compared to PEN's ROE of +0.13%. Regarding short-term risk, TMCI is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PEN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, TMCI is priced at $1.93, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SWAV's P/E ratio is 78.76. In terms of profitability, TMCI's ROE is -0.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, TMCI is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SWAV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ALGN has a market cap of 12.5B. Regarding current trading prices, TMCI is priced at $1.93, while ALGN trades at $173.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ALGN's P/E ratio is 29.17. In terms of profitability, TMCI's ROE is -0.62%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ALGN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, GMED has a market cap of 12.1B. Regarding current trading prices, TMCI is priced at $1.93, while GMED trades at $89.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas GMED's P/E ratio is 22.75. In terms of profitability, TMCI's ROE is -0.62%, compared to GMED's ROE of +0.12%. Regarding short-term risk, TMCI is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check GMED's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PODD has a market cap of 10.5B. Regarding current trading prices, TMCI is priced at $1.93, while PODD trades at $151.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PODD's P/E ratio is 43.45. In terms of profitability, TMCI's ROE is -0.62%, compared to PODD's ROE of +0.21%. Regarding short-term risk, TMCI is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check PODD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, GKOS has a market cap of 8B. Regarding current trading prices, TMCI is priced at $1.93, while GKOS trades at $135.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas GKOS's P/E ratio is -41.03. In terms of profitability, TMCI's ROE is -0.62%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, TMCI is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check GKOS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BIO has a market cap of 7B. Regarding current trading prices, TMCI is priced at $1.93, while BIO trades at $259.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BIO's P/E ratio is 43.18. In terms of profitability, TMCI's ROE is -0.62%, compared to BIO's ROE of +0.02%. Regarding short-term risk, TMCI is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BIO's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BIO-B has a market cap of 7B. Regarding current trading prices, TMCI is priced at $1.93, while BIO-B trades at $261.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BIO-B's P/E ratio is 42.93. In terms of profitability, TMCI's ROE is -0.62%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, TMCI is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BIO-B's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BRKR has a market cap of 6.4B. Regarding current trading prices, TMCI is priced at $1.93, while BRKR trades at $42.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BRKR's P/E ratio is -282.07. In terms of profitability, TMCI's ROE is -0.62%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, TMCI is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check BRKR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, TMCI is priced at $1.93, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas NARI's P/E ratio is -59.24. In terms of profitability, TMCI's ROE is -0.62%, compared to NARI's ROE of -0.00%. Regarding short-term risk, TMCI is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NARI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, IRTC has a market cap of 3.9B. Regarding current trading prices, TMCI is priced at $1.93, while IRTC trades at $117.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas IRTC's P/E ratio is -138.68. In terms of profitability, TMCI's ROE is -0.62%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, TMCI is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check IRTC's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, TMCI is priced at $1.93, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas AXNX's P/E ratio is -709.80. In terms of profitability, TMCI's ROE is -0.62%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, TMCI is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AXNX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, LIVN has a market cap of 3.6B. Regarding current trading prices, TMCI is priced at $1.93, while LIVN trades at $66.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas LIVN's P/E ratio is -14.87. In terms of profitability, TMCI's ROE is -0.62%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, TMCI is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check LIVN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, TMCI is priced at $1.93, while ITGR trades at $86.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ITGR's P/E ratio is 21.38. In terms of profitability, TMCI's ROE is -0.62%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, TMCI is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ITGR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, TMCI is priced at $1.93, while TMDX trades at $72.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas TMDX's P/E ratio is 14.97. In terms of profitability, TMCI's ROE is -0.62%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, TMCI is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check TMDX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, TMCI is priced at $1.93, while AXGN trades at $43.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas AXGN's P/E ratio is -68.97. In terms of profitability, TMCI's ROE is -0.62%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, TMCI is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AXGN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, TMCI is priced at $1.93, while ESTA trades at $74.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ESTA's P/E ratio is -43.37. In terms of profitability, TMCI's ROE is -0.62%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, TMCI is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check ESTA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, TMCI is priced at $1.93, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas NUVA's P/E ratio is 75.00. In terms of profitability, TMCI's ROE is -0.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, TMCI is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NUVA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, TMCI is priced at $1.93, while UFPT trades at $218.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas UFPT's P/E ratio is 24.98. In terms of profitability, TMCI's ROE is -0.62%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, TMCI is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check UFPT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, AORT has a market cap of 1.7B. Regarding current trading prices, TMCI is priced at $1.93, while AORT trades at $34.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas AORT's P/E ratio is 165.31. In terms of profitability, TMCI's ROE is -0.62%, compared to AORT's ROE of +0.02%. Regarding short-term risk, TMCI is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AORT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, TMCI is priced at $1.93, while AHCO trades at $11.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas AHCO's P/E ratio is -19.33. In terms of profitability, TMCI's ROE is -0.62%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, TMCI is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check AHCO's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, TMCI is priced at $1.93, while PRCT trades at $24.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PRCT's P/E ratio is -13.55. In terms of profitability, TMCI's ROE is -0.62%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, TMCI is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PRCT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, INSP has a market cap of 1.3B. Regarding current trading prices, TMCI is priced at $1.93, while INSP trades at $45.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas INSP's P/E ratio is 10.39. In terms of profitability, TMCI's ROE is -0.62%, compared to INSP's ROE of +0.18%. Regarding short-term risk, TMCI is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check INSP's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, TMCI is priced at $1.93, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas HSKA's P/E ratio is -62.49. In terms of profitability, TMCI's ROE is -0.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, TMCI is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check HSKA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $1.93, while TNDM trades at $18.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas TNDM's P/E ratio is -5.93. In terms of profitability, TMCI's ROE is -0.62%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, TMCI is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check TNDM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BFLY has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $1.93, while BFLY trades at $4.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BFLY's P/E ratio is -15.15. In terms of profitability, TMCI's ROE is -0.62%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, TMCI and BFLY have similar daily volatility (6.82).Check BFLY's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, TMCI is priced at $1.93, while AVNS trades at $24.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas AVNS's P/E ratio is -15.75. In terms of profitability, TMCI's ROE is -0.62%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, TMCI is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AVNS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $1.93, while CNMD trades at $37.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CNMD's P/E ratio is 21.08. In terms of profitability, TMCI's ROE is -0.62%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, TMCI is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CNMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $1.93, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SILK's P/E ratio is -18.96. In terms of profitability, TMCI's ROE is -0.62%, compared to SILK's ROE of -0.35%. Regarding short-term risk, TMCI is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SILK's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $1.93, while IRMD trades at $86.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas IRMD's P/E ratio is 47.14. In terms of profitability, TMCI's ROE is -0.62%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, TMCI is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check IRMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $1.93, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas FNA's P/E ratio is -19.83. In terms of profitability, TMCI's ROE is -0.62%, compared to FNA's ROE of -0.35%. Regarding short-term risk, TMCI is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check FNA's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $1.93, while IART trades at $14.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas IART's P/E ratio is -2.17. In terms of profitability, TMCI's ROE is -0.62%, compared to IART's ROE of -0.48%. Regarding short-term risk, TMCI is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check IART's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ATEC has a market cap of 1.1B. Regarding current trading prices, TMCI is priced at $1.93, while ATEC trades at $6.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ATEC's P/E ratio is -7.27. In terms of profitability, TMCI's ROE is -0.62%, compared to ATEC's ROE of -1.42%. Regarding short-term risk, TMCI is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check ATEC's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, LMRI has a market cap of 989M. Regarding current trading prices, TMCI is priced at $1.93, while LMRI trades at $10.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas LMRI's P/E ratio is -15.59. In terms of profitability, TMCI's ROE is -0.62%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, TMCI is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check LMRI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, INMD has a market cap of 862.3M. Regarding current trading prices, TMCI is priced at $1.93, while INMD trades at $13.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas INMD's P/E ratio is 9.52. In terms of profitability, TMCI's ROE is -0.62%, compared to INMD's ROE of +0.15%. Regarding short-term risk, TMCI is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check INMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, TMCI is priced at $1.93, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CSII's P/E ratio is -20.83. In terms of profitability, TMCI's ROE is -0.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, TMCI is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CSII's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SSII has a market cap of 819.5M. Regarding current trading prices, TMCI is priced at $1.93, while SSII trades at $4.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SSII's P/E ratio is -68.25. In terms of profitability, TMCI's ROE is -0.62%, compared to SSII's ROE of -0.30%. Regarding short-term risk, TMCI is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check SSII's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CBLL has a market cap of 762.4M. Regarding current trading prices, TMCI is priced at $1.93, while CBLL trades at $20.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CBLL's P/E ratio is -13.79. In terms of profitability, TMCI's ROE is -0.62%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, TMCI is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CBLL's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BVS has a market cap of 737.9M. Regarding current trading prices, TMCI is priced at $1.93, while BVS trades at $10.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BVS's P/E ratio is 33.06. In terms of profitability, TMCI's ROE is -0.62%, compared to BVS's ROE of +0.16%. Regarding short-term risk, TMCI is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check BVS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, TMCI is priced at $1.93, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CRY's P/E ratio is 425.71. In terms of profitability, TMCI's ROE is -0.62%, compared to CRY's ROE of +0.02%. Regarding short-term risk, TMCI is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CRY's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BWAY has a market cap of 643.3M. Regarding current trading prices, TMCI is priced at $1.93, while BWAY trades at $16.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BWAY's P/E ratio is 91.11. In terms of profitability, TMCI's ROE is -0.62%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, TMCI is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check BWAY's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CTKB has a market cap of 634.4M. Regarding current trading prices, TMCI is priced at $1.93, while CTKB trades at $4.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CTKB's P/E ratio is -9.49. In terms of profitability, TMCI's ROE is -0.62%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, TMCI is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CTKB's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, NPCE has a market cap of 615M. Regarding current trading prices, TMCI is priced at $1.93, while NPCE trades at $18.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas NPCE's P/E ratio is -27.45. In terms of profitability, TMCI's ROE is -0.62%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, TMCI is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check NPCE's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, TMCI is priced at $1.93, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SRDX's P/E ratio is -34.66. In terms of profitability, TMCI's ROE is -0.62%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, TMCI is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SRDX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, TMCI is priced at $1.93, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas APEN's P/E ratio is -9.43. In terms of profitability, TMCI's ROE is -0.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, TMCI is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check APEN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SIBN has a market cap of 574.7M. Regarding current trading prices, TMCI is priced at $1.93, while SIBN trades at $12.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SIBN's P/E ratio is -29.52. In terms of profitability, TMCI's ROE is -0.62%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, TMCI is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SIBN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, TCMD has a market cap of 571.1M. Regarding current trading prices, TMCI is priced at $1.93, while TCMD trades at $25.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas TCMD's P/E ratio is 29.10. In terms of profitability, TMCI's ROE is -0.62%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, TMCI is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check TCMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, TMCI is priced at $1.93, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, TMCI's ROE is -0.62%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, TMCI is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ZIMV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PACB has a market cap of 519.4M. Regarding current trading prices, TMCI is priced at $1.93, while PACB trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PACB's P/E ratio is -0.95. In terms of profitability, TMCI's ROE is -0.62%, compared to PACB's ROE of -11.23%. Regarding short-term risk, TMCI is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check PACB's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CERS has a market cap of 519M. Regarding current trading prices, TMCI is priced at $1.93, while CERS trades at $2.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CERS's P/E ratio is -51.80. In terms of profitability, TMCI's ROE is -0.62%, compared to CERS's ROE of -0.15%. Regarding short-term risk, TMCI is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check CERS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, VREX has a market cap of 509.6M. Regarding current trading prices, TMCI is priced at $1.93, while VREX trades at $12.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas VREX's P/E ratio is -7.41. In terms of profitability, TMCI's ROE is -0.62%, compared to VREX's ROE of -0.14%. Regarding short-term risk, TMCI is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check VREX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, OFIX has a market cap of 489.8M. Regarding current trading prices, TMCI is priced at $1.93, while OFIX trades at $12.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas OFIX's P/E ratio is -5.24. In terms of profitability, TMCI's ROE is -0.62%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, TMCI and OFIX have similar daily volatility (6.82).Check OFIX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, KIDS has a market cap of 440.5M. Regarding current trading prices, TMCI is priced at $1.93, while KIDS trades at $17.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas KIDS's P/E ratio is -10.21. In terms of profitability, TMCI's ROE is -0.62%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, TMCI is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check KIDS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, DCTH has a market cap of 390.7M. Regarding current trading prices, TMCI is priced at $1.93, while DCTH trades at $11.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas DCTH's P/E ratio is 160.64. In terms of profitability, TMCI's ROE is -0.62%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, TMCI is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check DCTH's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, LAB has a market cap of 380.6M. Regarding current trading prices, TMCI is priced at $1.93, while LAB trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas LAB's P/E ratio is -6.50. In terms of profitability, TMCI's ROE is -0.62%, compared to LAB's ROE of +0.17%. Regarding short-term risk, TMCI is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check LAB's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PMI has a market cap of 353.5M. Regarding current trading prices, TMCI is priced at $1.93, while PMI trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PMI's P/E ratio is -0.30. In terms of profitability, TMCI's ROE is -0.62%, compared to PMI's ROE of +2.17%. Regarding short-term risk, TMCI is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check PMI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CLPT has a market cap of 343.9M. Regarding current trading prices, TMCI is priced at $1.93, while CLPT trades at $11.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CLPT's P/E ratio is -13.03. In terms of profitability, TMCI's ROE is -0.62%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, TMCI is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check CLPT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, VMD has a market cap of 327.7M. Regarding current trading prices, TMCI is priced at $1.93, while VMD trades at $8.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas VMD's P/E ratio is 23.01. In terms of profitability, TMCI's ROE is -0.62%, compared to VMD's ROE of +0.11%. Regarding short-term risk, TMCI is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check VMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, TMCI is priced at $1.93, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SMLR's P/E ratio is 3.92. In terms of profitability, TMCI's ROE is -0.62%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, TMCI is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SMLR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, MASS has a market cap of 301.3M. Regarding current trading prices, TMCI is priced at $1.93, while MASS trades at $8.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas MASS's P/E ratio is -8.67. In terms of profitability, TMCI's ROE is -0.62%, compared to MASS's ROE of -0.26%. Regarding short-term risk, TMCI is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check MASS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CATX has a market cap of 281M. Regarding current trading prices, TMCI is priced at $1.93, while CATX trades at $3.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CATX's P/E ratio is -2.71. In terms of profitability, TMCI's ROE is -0.62%, compared to CATX's ROE of -0.41%. Regarding short-term risk, TMCI is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check CATX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, RXST has a market cap of 279.8M. Regarding current trading prices, TMCI is priced at $1.93, while RXST trades at $6.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas RXST's P/E ratio is -7.14. In terms of profitability, TMCI's ROE is -0.62%, compared to RXST's ROE of -0.14%. Regarding short-term risk, TMCI is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check RXST's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, TMCI is priced at $1.93, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas MGRM's P/E ratio is -11.11. In terms of profitability, TMCI's ROE is -0.62%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, TMCI is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check MGRM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, AVR has a market cap of 234.7M. Regarding current trading prices, TMCI is priced at $1.93, while AVR trades at $6.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas AVR's P/E ratio is -2.50. In terms of profitability, TMCI's ROE is -0.62%, compared to AVR's ROE of -5.28%. Regarding short-term risk, TMCI is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check AVR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SGHT has a market cap of 233.3M. Regarding current trading prices, TMCI is priced at $1.93, while SGHT trades at $4.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SGHT's P/E ratio is -5.84. In terms of profitability, TMCI's ROE is -0.62%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, TMCI is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SGHT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, TMCI is priced at $1.93, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas NVRO's P/E ratio is -1.91. In terms of profitability, TMCI's ROE is -0.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, TMCI is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NVRO's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SENS has a market cap of 224M. Regarding current trading prices, TMCI is priced at $1.93, while SENS trades at $5.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SENS's P/E ratio is -3.23. In terms of profitability, TMCI's ROE is -0.62%, compared to SENS's ROE of -1.04%. Regarding short-term risk, TMCI is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check SENS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, PROF has a market cap of 218.2M. Regarding current trading prices, TMCI is priced at $1.93, while PROF trades at $7.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas PROF's P/E ratio is -5.11. In terms of profitability, TMCI's ROE is -0.62%, compared to PROF's ROE of -0.80%. Regarding short-term risk, TMCI is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check PROF's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ELMD has a market cap of 214.9M. Regarding current trading prices, TMCI is priced at $1.93, while ELMD trades at $25.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ELMD's P/E ratio is 25.21. In terms of profitability, TMCI's ROE is -0.62%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, TMCI is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ELMD's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, TMCI is priced at $1.93, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas EYES's P/E ratio is N/A. In terms of profitability, TMCI's ROE is -0.62%, compared to EYES's ROE of -3.17%. Regarding short-term risk, TMCI is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check EYES's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, ANIK has a market cap of 201.2M. Regarding current trading prices, TMCI is priced at $1.93, while ANIK trades at $15.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas ANIK's P/E ratio is -19.14. In terms of profitability, TMCI's ROE is -0.62%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, TMCI is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check ANIK's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, INGN has a market cap of 194M. Regarding current trading prices, TMCI is priced at $1.93, while INGN trades at $7.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas INGN's P/E ratio is -8.26. In terms of profitability, TMCI's ROE is -0.62%, compared to INGN's ROE of -0.12%. Regarding short-term risk, TMCI is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check INGN's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, QTI has a market cap of 192.4M. Regarding current trading prices, TMCI is priced at $1.93, while QTI trades at $7.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas QTI's P/E ratio is -3.53. In terms of profitability, TMCI's ROE is -0.62%, compared to QTI's ROE of +3.64%. Regarding short-term risk, TMCI is more volatile compared to QTI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check QTI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, TMCI is priced at $1.93, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas BSGM's P/E ratio is -5.81. In terms of profitability, TMCI's ROE is -0.62%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, TMCI is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check BSGM's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, CVRX has a market cap of 186.2M. Regarding current trading prices, TMCI is priced at $1.93, while CVRX trades at $7.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas CVRX's P/E ratio is -3.47. In terms of profitability, TMCI's ROE is -0.62%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, TMCI is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check CVRX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, TMCI is priced at $1.93, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas MDGS's P/E ratio is -0.27. In terms of profitability, TMCI's ROE is -0.62%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, TMCI is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check MDGS's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, TLSI has a market cap of 172.9M. Regarding current trading prices, TMCI is priced at $1.93, while TLSI trades at $4.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas TLSI's P/E ratio is -2.48. In terms of profitability, TMCI's ROE is -0.62%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, TMCI is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check TLSI's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, TMCI is priced at $1.93, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas QIPT's P/E ratio is -15.87. In terms of profitability, TMCI's ROE is -0.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, TMCI is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check QIPT's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, QTRX has a market cap of 154.9M. Regarding current trading prices, TMCI is priced at $1.93, while QTRX trades at $3.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas QTRX's P/E ratio is -1.31. In terms of profitability, TMCI's ROE is -0.62%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, TMCI is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check QTRX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, HYPR has a market cap of 143M. Regarding current trading prices, TMCI is priced at $1.93, while HYPR trades at $1.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas HYPR's P/E ratio is -4.07. In terms of profitability, TMCI's ROE is -0.62%, compared to HYPR's ROE of -0.97%. Regarding short-term risk, TMCI is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check HYPR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, SNWV has a market cap of 136.7M. Regarding current trading prices, TMCI is priced at $1.93, while SNWV trades at $15.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas SNWV's P/E ratio is 38.80. In terms of profitability, TMCI's ROE is -0.62%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, TMCI is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check SNWV's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, EDAP has a market cap of 135.7M. Regarding current trading prices, TMCI is priced at $1.93, while EDAP trades at $3.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas EDAP's P/E ratio is -4.64. In terms of profitability, TMCI's ROE is -0.62%, compared to EDAP's ROE of -1.12%. Regarding short-term risk, TMCI is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check EDAP's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, NNOX has a market cap of 123.9M. Regarding current trading prices, TMCI is priced at $1.93, while NNOX trades at $1.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas NNOX's P/E ratio is -1.53. In terms of profitability, TMCI's ROE is -0.62%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, TMCI is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check NNOX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, APYX has a market cap of 121.7M. Regarding current trading prices, TMCI is priced at $1.93, while APYX trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas APYX's P/E ratio is -10.78. In terms of profitability, TMCI's ROE is -0.62%, compared to APYX's ROE of -1.18%. Regarding short-term risk, TMCI is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for TMCI.Check APYX's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, FONR has a market cap of 116.6M. Regarding current trading prices, TMCI is priced at $1.93, while FONR trades at $18.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas FONR's P/E ratio is 16.42. In terms of profitability, TMCI's ROE is -0.62%, compared to FONR's ROE of +0.04%. Regarding short-term risk, TMCI is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check FONR's competition here

TMCI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TMCI stands at 124.4M. In comparison, RPID has a market cap of 115.3M. Regarding current trading prices, TMCI is priced at $1.93, while RPID trades at $2.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TMCI currently has a P/E ratio of -2.09, whereas RPID's P/E ratio is -2.52. In terms of profitability, TMCI's ROE is -0.62%, compared to RPID's ROE of -0.95%. Regarding short-term risk, TMCI is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for TMCI.Check RPID's competition here